Experienced in Nephrocalcinosis

Jesper A. Johannesen

Copenhagen, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Nephrocalcinosis
Copenhagen, DK 
OverviewLocationsClinical Research

Overview

Jesper Johannesen practices in Copenhagen, Denmark. Mr. Johannesen is rated as an Experienced expert by MediFind in the treatment of Nephrocalcinosis. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Serum Sickness, and Congenital Hyperinsulinism.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Nephrocalcinosis.

Gender
Male

Locations

Copenhagen, Denmark
Other Locations
Herlev, Denmark
Gentofte, Denmark
Hellerup, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Recruiting
Publish Date: June 03, 2025
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
View 1 Less Clinical Trial

64 Total Publications

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Journal: Lancet (London, England)
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Johannesen's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile